FDA also approved the Ventana CLDN18 (43-14A) RxDx Assay, from Ventana Medical Systems, Inc. and Roche Diagnostics, to ...

Rechallenging patients with ICIs may not be beneficial in advanced RCC, but Tivozanib monotherapy shows promise as an ...

Panelists discuss how the introduction of adjuvant immunotherapy has influenced their first-line treatment decisions for ...

The FDA approved zolbetuximab (Vyloy), a claudin 18.2 (CLDN18.2)-directed cytolytic antibody, in combination with ...

Tyra Biosciences receives an upgrade from BofA, raising the price target to $31. The upgrade follows promising preclinical ...

Adding immunotherapy to platinum-gemcitabine chemotherapy can improve outcomes in patients with advanced urothelial carcinoma, but that may depend on the platinum agent used, data suggest.

Adenocarcinoma incidence was also significantly higher in hr-HPV-negative cervical cancer patients [RR=2.36, 95%CI (1.44–3.89), P=0.005]. Conclusions: Cervical cancer patients not infected by hr-HPV ...

Astellas Pharma Inc. (ALPMY, ALPMY) said that the U.S. Food and Drug Administration has approved VYLOY (zolbetuximab-clzb) in ...

Vyloy is the first CLDN 18.2-targeted treatment to reach the US market alongside Roche's Ventana CLDN18 RxDx Assay for identifying eligible patients.

After a prior rejection, Astellas can head into the weekend celebrating a class-first FDA approval for its new gastric cancer ...

Dr. Jianjun ZOU, General Manager and CEO of Junshi Biosciences, said, “As of now, toripalimab has been approved for marketing in over 30 countries and regions across three continents worldwide. With ...

It may soon be possible to determine which patients with a type of liver cancer called hepatocellular carcinoma would benefit ...